semaglutide affect kidneys in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial Semaglutide in Diabetic Kidney Disease:

A 2022 clinical trial of people taking semaglutide found that 99% of gastrointestinal side effects were non-serious though it's worth noting the study was funded by Novo Nordisk, the maker of Ozempic and Wegovy

There are several options in the market, but you need to identify your goal

Using sterile water beyond a single use or sharing it between patients can risk contamination, since it has no agent to suppress bacterial growth

Novo Nordisk presents 4 new analyses on oral semaglutide 25 mg (Wegovy in a pill) at ObesityWeek 2025, including demonstrated reductions in cardiovascular risk factors

Medicine is a relationship

This dual mechanism distinguishes it from traditional GLP-1 therapies, which target only the GLP-1 pathway